MRM Proteomics Inc, Montreal, and Biodesix, Boulder, Colo, have entered into a partnership to develop novel assays to answer critical clinical questions within the lung cancer continuum of care.
Christoph Borchers, MRM Proteomics.
Under the terms of the deal, MRM Proteomics will grant Biodesix rights to utilize its proprietary mass spectrometry technology, immuno-matrix-assisted laser desorption ionization (iMALDI) MS, to advance its blood-based lung cancer diagnostics. Both companies share a commitment to advancing the accuracy and accessibility of precision medicine strategies for cancer patients.
“Examining a patient’s genomic data has advanced targeted therapies. However, proteins are the targets of most drugs and hold the key to unlocking the promise of precision medicine,” says Christoph Borchers, chief scientific officer at MRM Proteomics. “Biodesix is a natural partner for our proteomic technology, because they are committed to a multiomics approach to reveal a more complete molecular profile of lung cancer in the body. We believe that this partnership will produce much-needed advances in the proteomic space and lead to more-precise lung cancer diagnostic tools that can help guide treatment decisions.”
Scott Hutton, Biodesix.
Lung cancer is a leading cause of cancer deaths worldwide. The ability to diagnose cancer at an early stage can improve overall survival rates; the ability to rule out cancer for those at risk can reduce patient anxiety and unnecessary procedures. Precision diagnostic tools are needed to give patients and clinicians accurate, timely information. The partnership of MRM Proteomics and Biodesix underscores the role of proteomics in delivering these tools.
“Elevating the importance of proteomics in revealing the full complexity of cancer is critical to getting patients the right treatment at the right time,” says Scott Hutton, COO at Biodesix. “MRM Proteomics is a leader in providing technologies that can help us unleash this potential.”
For further information, visit Biodesix and MRM Proteomics.
